Publications & Posters
Scholary publications
Spinal Muscular Atrophy
Apitegromab
June 2022
CURE SMA Annual Conference
Topaz Extension: 24-Month Efficacy and Safety: Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy
Apitegromab
June 2022
CURE SMA Annual Conference
Treatment Effects Among Patients with Type 2 and Type 3 SMA: Directly Reported by Patients and Caregivers from the TOPAZ Clinical Trial
Spinal Muscular Atrophy
Apitegromab
April 2022
2022 European Paediatric Neurology Society Congress (EPNS)
Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (Presentation)
Spinal Muscular Atrophy
Apitegromab
April 2022
American Academy of Neurology (AAN) 2022 Annual Meeting
Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (P15.005)
Spinal Muscular Atrophy
Apitegromab
March 2022
2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Apitegromab in SMA: An Analysis of PK/PD Relationships to Efficacy in Ambulatory Patients from the TOPAZ Trial (#72)
Immuno-Oncology
SRK-181
January 2022
2nd Annual TGFβ for Immuno-Oncology Drug Development Summit
